Author:
Sellers Katherine,Allen Thaddeus D.,Bousamra Michael,Tan JinLian,Méndez-Lucas Andrés,Lin Wei,Bah Nourdine,Chernyavskaya Yelena,MacRae James I.,Higashi Richard M.,Lane Andrew N.,Fan Teresa W.-M.,Yuneva Mariia O.
Funder
Cancer Research UK
Wellcome Trust
RCUK | Medical Research Council
National Institute of Health, USA
University of Louisville
Publisher
Springer Science and Business Media LLC
Reference63 articles.
1. Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., Rosso, S., Coebergh, J. W., Comber, H. et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur. J. Cancer 49, 1374–1403 (2013).
2. Matsuda, T. & Machii, R. Morphological distribution of lung cancer from Cancer Incidence in Five Continents Vol. X. Jpn J. Clin. Oncol. 45, 404 (2015).
3. Silva, A. P., Coelho, P. V., Anazetti, M., Simioni, P. U. Targeted therapies for the treatment of non-small-cell lung cancer: monoclonal antibodies and biological inhibitors. Hum. Vaccin. Immunother. 13, 843–853 (2017).
4. Fala, L. Portrazza (Necitumumab), an IgG1 monoclonal antibody, FDA approved for advanced squamous non-small-cell lung cancer. Am. Health Drug Benefits 9(Spec Feature), 119–122 (2016).
5. Guo, L., Zhang, H., Chen, B. Nivolumab as Programmed Death-1 (PD-1) inhibitor for targeted immunotherapy in tumor. J. Cancer 8, 410–416 (2017).
Cited by
32 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献